Comparison of Two Lenalidomide-Based Triplets in Newly Diagnosed Multiple Myeloma
Stefan Knop, MD, of the Würzburg University Hospital in Germany, and colleagues conducted the first study comparing two lenalidomide-based triplet therapies for patients with multiple myeloma prior to stem cell transplantation: bortezomib, lenalidomide, and dexamethasone (VRD) and lenalidomide, doxorubicin, and dexamethasone (RAD). Both therapies demonstrated comparable efficacy, and the results were presented at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting (Abstract 8001).
A total of 469 patients were enrolled between May 2012 and June 2016. One group received three 4-week RAD cycles (n=232), and the second group received three 3-week VRD cycles (n=237). Comparable numbers of patients in both the RAD and VRD therapy groups completed all induction cycles (89.7% and 93.2%, respectively). The post-induction complete response rate was 11.8% with RAD and 13% with VRD.
Treatment-emergent serious adverse events occurred in 47 patients treated with RAD (20.3%) and 35 patients treated with VRD (14.8%). Treatment-related mortality did not occur in either arm.
The investigators plan to assemble follow-up data to analyze time-dependent study endpoints.